Rapid Communication
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 7, 2006; 12(13): 2075-2079
Published online Apr 7, 2006. doi: 10.3748/wjg.v12.i13.2075
Table 1 Backgrounds of patients without or with history of treatment
Patients without history of HCC(n=37)Patients with history of HCC(n=84)P value
Age (yr)66.4 ± 9.967.0 ± 8.1NS
Sex (male ∶ female)32∶564∶20NS
Frequency of positive for anti-HCV72%81%NS
TNM stage (II ∶ III)12∶2535∶49NS
Tumor size (mm)46.4 ± 23.527.7 ± 16.1P < 0.01
Number of tumors ( ≤3 ∶ >3)21∶1623∶61P < 0.01
Monolobular ∶ bilobular17∶2027∶57NS
Child-Pugh class (A ∶ B)27∶1048∶36NS
Alanine transferase (IU/L)63.8 ± 45.182.1 ± 64.3P = 0.07
AFP ( ≤100 ∶ >100 ng/mL)23∶1453∶31NS
TAE with or without anti-cancer medication13∶2417∶67NS
Average number of past treatments-2.9 ± 2.2-
History of hepatectomy-18%-
Average observation period (d)557.6 ± 377.0493.6 ± 390.6NS
Table 2 Univariate analysis of patients with past treatment for HCC (n=84)
FactorsNumberHazard ratio95% CIP value
Age (= and < 65 ∶ > 65)38∶460.990.95-1.02NS
Sex (male ∶ female)64∶201.020.54-1.93NS
Anti-HCV (positive ∶ negative)67∶171.310.64-2.67NS
TNM stage (II ∶ III)35∶491.570.83-3.00NS
Tumor size (mm)-10.98-1.02NS
Number of tumors ( ≤ 3 ∶ > 3)23∶610.880.47-1.67NS
Monolobular : bilobular27∶5721.04-3.86P < 0.05
Child-Pugh class (A ∶ B)48∶361.070.59-1.95NS
AFP ( ≤100 ∶ >100 ng/mL)53∶311.91.03-3.48P < 0.05
History of hepatectomy (negative ∶ positive)69∶151.630.72-3.70NS
Number of past treatments-1.050.93-1.19NS
Table 3 Multivariate analysis of patients with past treatment for HCC (n=84)
FactorsHazard ratio95% CIP value
Existence of bilobular tumors2.371.19 - 4.71P < 0.05
AFP (>100 ng/mL)2.241.19 - 4.23P < 0.05

  • Citation: Hiraoka A, Kumagi T, Hirooka M, Uehara T, Kurose K, Iuchi H, Hiasa Y, Matsuura B, Michitaka K, Kumano S, Tanaka H, Yamashita Y, Horiike N, Mochizuki T, Onji M. Prognosis following transcatheter arterial embolization for 121 patients with unresectable hepatocellular carcinoma with or without a history of treatment. World J Gastroenterol 2006; 12(13): 2075-2079
  • URL: https://www.wjgnet.com/1007-9327/full/v12/i13/2075.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v12.i13.2075